Depolarizing actions of gamma-aminobutyric acid and related compounds on rat superior cervical ganglia in vitro.
1 Potential changes in rat superior cervical ganglia were recorded in vitro with surface electrodes.2 gamma-aminobutyric acid (GABA) produced a transient, low-amplitude ganglion depolarization at rest, and a transient hyperpolarization in ganglia depolarized by carbachol. Depolarization was not prevented by preganglionic denervation. The log dose-response curve for depolarization was sigmoid with a mean ED(50) of 12.5 muM.3 The ganglion was depolarized in similar manner by the following compounds (mean molar potencies relative to GABA (=1) in brackets): 3-aminopropane sulphonic acid (3.4), gamma-amino-beta-hydroxybutyric acid (0.27), beta-guanidino-propionic acid (0.12), guanidinoacetic acid (0.057), delta-aminovaleric acid (0.048), beta-alanine (0.01), 2,4-diaminobutyric acid, gamma-guanidinobutyric acid, taurine and N-methyl-GABA (all <0.01). The following compounds did not depolarize the ganglion at 10 mM concentrations: alpha- and beta-amino-n-butyric acids, alpha-amino-iso-butyric acid, glycine and glutamic acid.4 Depolarization declined in the continued presence of GABA. Ganglia thus ;desensitized' to GABA showed a diminished response to other amino acids but not to carbachol.5 The effect of GABA was not antagonized by hyoscine and hexamethonium in combination, in concentrations sufficient to block responses to carbachol.6 Responses to GABA were blocked more readily than those to carbachol by bicuculline (IC(50), 14 muM) and picrotoxin (IC(50), 37 muM). Strychnine (IC(50), 73 muM) was a relatively weak and less selective GABA-antagonist.7 It is concluded that sympathetic ganglion cells possess receptors for GABA and related amino acids which are (a) different from the acetylcholine receptors and (b) similar to GABA receptors in the central nervous system.
D000409:Alanine / Q000494:pharmacology; D000613:Aminobutyrates / Q000494:pharmacology*; D000621:Aminoisobutyric Acids / Q000494:pharmacology; D000818:Animals; D002217:Carbachol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D018756:GABA Antagonists; D005725:Ganglia, Autonomic / Q000187:drug effects*; D005973:Glutamine / Q000494:pharmacology; D005998:Glycine / Q000494:pharmacology; D006584:Hexamethonium Compounds / Q000494:pharmacology; D006885:Hydroxybutyrates / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D010852:Picrotoxin / Q000494:pharmacology; D051381:Rats; D011950:Receptors, Cholinergic; D012601:Scopolamine / Q000494:pharmacology; D013331:Strychnine / Q000494:pharmacology; D013451:Sulfonic Acids / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000187:drug effects; D013654:Taurine / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D000409:Alanine; D000613:Aminobutyrates; D000621:Aminoisobutyric Acids; D002217:Carbachol; D018756:GABA Antagonists; D005973:Glutamine; D005998:Glycine; D006584:Hexamethonium Compounds; D006885:Hydroxybutyrates; D007546:Isoquinolines; D010852:Picrotoxin; D011950:Receptors, Cholinergic; D012601:Scopolamine; D013331:Strychnine; D013451:Sulfonic Acids; D013654:Taurine; D005680:gamma-Aminobutyric Acid